首页> 外文期刊>Journal of Medical Microbiology: An Official Journal of the Pathological Society of Great Britain and Ireland >Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species
【24h】

Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species

机译:脲原体中常见的拓扑异构酶IV突变与氟喹诺酮耐药相关

获取原文
           

摘要

This study aimed to investigate the role of quinolone resistance-determining regions (QRDRs) of DNA gyrase (encoded by gyrA and gyrB) and topoisomerase IV (encoded by parC and parE) associated with fluoroquinolone resistance. A total of 114 Ureaplasma spp. strains, isolated from clinical female patients with symptomatic infection, were tested for species distribution and susceptibility to four fluoroquinolones. Moreover, we analysed the QRDRs and compared these with 14 ATCC reference strains of Ureaplasma spp. serovars to identify mutations that caused antimicrobial resistance. Our study indicated that moxifloxacin was the most effective fluoroquinolone against Ureaplasma spp. (MIC range: 0.125–32 μg ml? 1). However, extremely high MICs were estimated for ciprofloxacin (MIC range: 1–256 μg ml? 1) and ofloxacin (MIC range: 0.5–128 μg ml? 1), followed by levofloxacin (MIC range: 0.5–64 μg ml? 1). Seven amino acid substitutions were discovered in GyrB, ParC and ParE, but not in GyrA. Ser-83 → Leu/Trp (C248T/G) in ParC and Arg-448 → Lys (G1343A) in ParE, which were potentially responsible for fluoroquinolone resistance, were observed in 89 (77.2 %) and three (2.6 %) strains, respectively. Pro-462 → Ser (C1384T), Asn-481 → Ser (A1442G) and Ala-493 → Val (C1478T) in GyrB and Met-105 → Ile (G315T) in ParC seemed to be neutral polymorphisms, and were observed and occurred along with the amino acid change of Ser-83 → Leu (C248T) in ParC. Interestingly, two novel mutations of ParC and ParE were independently found in four strains. These observations suggest that amino acid mutation in topoisomerase IV appears to be the leading cause of fluoroquinolone resistance, especially the mutation of Ser-83 → Leu (C248T) in ParC. Moxifloxacin had the best activity against strains with Ser-83 → Leu mutation.
机译:这项研究旨在调查DNA促旋酶(由gyrA和gyrB编码)和拓扑异构酶IV(由parC和parE编码)的喹诺酮耐药性决定区域(QRDRs)与氟喹诺酮耐药性相关的作用。共有114种脲原体。从临床上有症状感染的女性患者中分离出的菌株,进行了物种分布和对四种氟喹诺酮类药物的敏感性测试。此外,我们分析了QRDR并将其与14种ATCC参考菌株的Ureaplasma spp比较。可以鉴定引起抗菌素耐药性的突变。我们的研究表明莫西沙星是最有效的抗脲原体的氟喹诺酮。 (MIC范围:0.125–32μgml?1)。但是,据估计环丙沙星(MIC范围:1–256μgml?1)和氧氟沙星(MIC范围:0.5–128μgml?1)的MIC极高,其次是左氧氟沙星(MIC范围:0.5–64μgml?1)。 )。在GyrB,ParC和ParE中发现了七个氨基酸取代,但在GyrA中未发现。在89株(77.2%)和3株(2.6%)菌株中观察到ParC中的Ser-83→Leu / Trp(C248T / G)和ParE中的Arg-448→Lys(G1343A),这可能与氟喹诺酮耐药有关。分别。在GyrB和Met-105中的Pro-462→Ser(C1384T),Asn-481→Ser(A1442G)和Ala-493→Val(C1478T)→在ParC中的Ile(G315T)似乎是中性多态性,已被观察到并发生以及ParC中Ser-83→Leu(C248T)的氨基酸变化。有趣的是,在四个菌株中分别发现了两个新的ParC和ParE突变。这些观察结果表明,拓扑异构酶IV中的氨基酸突变似乎是引起氟喹诺酮耐药的主要原因,尤其是ParC中Ser-83→Leu(C248T)的突变。莫西沙星对具有Ser-83→Leu突变的菌株具有最佳活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号